Cover Image
市场调查报告书

T细胞免疫疗法市场 (第3版):2018-2030年

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

出版商 ROOTS ANALYSIS 商品编码 342155
出版日期 内容信息 英文 850 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
T细胞免疫疗法市场 (第3版):2018-2030年 T-Cell Immunotherapy Market (3rd Edition), 2018-2030
出版日期: 2018年05月11日 内容信息: 英文 850 Pages
简介

本报告提供T细胞免疫疗法市场相关调查分析,以目前的市场情势与未来的可能性为焦点,提供主要企业,开发中产品的开发阶段,联盟动向,创新的技术,治疗领域,竞争情形等系统性信息。

第1章 序文

第2章 摘要整理

第3章 简介

第4章 社群媒体上的新兴趋势

  • 本章概要
  • Twitter上趋势

第5章 市场形势

  • 本章概要
  • T细胞免疫疗法:有前途的开发平台

第6章 主要考察

  • 本章概要
  • T细胞免疫疗法:标的抗原的畅销度分析
  • T细胞免疫疗法:CAR-T临床实验趋势
  • T细胞免疫疗法:临床实验概要

第7章 嵌合抗原受体表现T (CAR-T) 细胞疗法

  • 简介
  • 开发的过程
  • 关键意见领袖
  • 嵌合抗原受体的解剖学配置
  • CAR-T结构分析
  • 嵌合抗原受体的开发
  • CAR-T细胞的开发
  • 通用CAR-T细胞
  • 给药途径
  • 毒性问题
  • 毒性问题的对应
  • CD19:富有魅力的标的
  • 其他标的
  • CAR-T疗法的课题
  • Kymriah ® / Tisagenlecleucel / CTL019 (Novartis)
  • Yescarta ® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
  • JCAR (Juno Therapeutics)
  • CAR-T Series (Cellular Biomedicine Group)
  • CD19 CAR (TaKaRa BIO))
  • Dual Targeting CAR-T Cell Therapies (Autolus)
  • CAR-T Therapies (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)

第8章 T细胞受体 (TCR) 型疗法

  • 简介
  • T细胞受体结构
  • CAR和TCR的差异
  • 作用机制
  • 关键意见领袖
  • 安全性的问题
  • 抗原特异性T细胞受体的必要条件
  • 强化抗肿瘤效果的策略
  • SPEAR ® T-Cells (Adaptimmune)
  • ALT-801 (AltorBioScience)
  • IMCgp100 (Immunocore)
  • JTCR016 (Juno Therapeutics)
  • CMD-602 / WT1 TCR Therapy (Cell Medica)
  • TBI-1301 (TaKaRa BIO)

第9章 肿瘤浸润淋巴球 (TIL) 型疗法

  • 本章概要
  • 开发的过程
  • 关键意见领袖
  • 提高功效的研究策略
  • 预后诊断工具
  • 制造工程
  • Autologous TIL Therapies (Iovance Biotherapeutics)
  • TIL (Nantes University Hospital)
  • TIL (Netherlands Cancer Institute)

第10章 T细胞疗法主要的治疗领域

  • 本章概要
  • 骨髓恶性肿瘤
    • 白血病和淋巴瘤
    • 多发性骨髓瘤
  • 固态肿瘤
    • 转移性黑色素瘤
    • 肺癌
    • 膀胱癌
    • 肾脏癌
    • 卵巢癌
    • 乳癌

第11章 新兴技术

  • 本章概要
  • 基因编辑技术
  • 改善特性的T细胞疗法设计

第11章 夥伴关系和合作

  • 本章概要
  • 夥伴关系模式的种类
  • 联盟·合作

第13章 融资·投资分析

  • 本章概要
  • 融资的种类
  • 融资·投资分析

第14章 其他T细胞免疫疗法

  • 本章概要
  • 其他T细胞免疫疗法
  • 控制性T细胞(Treg)疗法
  • T细胞型疫苗
  • 病毒驱动的T细胞疗法
  • 岩藻糖化技术平台
  • PD-1基因敲除工程T细胞治疗
  • TAC-T细胞疗法
  • Gama Delta T细胞免疫疗法

第15章 案例研究:细胞疗法的制造

  • 本章概要
  • 简介
  • 主要课题
  • 目前趋势
  • 制造网站主要的讨论事项
  • 法规形势

第16章 案例研究:原价分析

  • 本章概要
  • 影响细胞/基因疗法高价的因素
  • T细胞免疫疗法的费用模式
  • T细胞免疫疗法的医疗费偿付的讨论事项

第17章 市场规模·机会分析

  • 本章概要
  • 调查范围·限制事项
  • 预测手法
  • 整体T细胞免疫疗法市场
  • T细胞免疫疗法市场:各产品的销售额预测

第18章 puromoshonaru分析

第19章 企业简介

  • 本章概要
  • Adaptimmune Therapeutics
  • Autolus
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Cell Medica
  • Cellectis
  • Cellular Biomedicine Group
  • Immunocore
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics
  • Kite Pharma (A Gilead Sciences Company)
  • Lion TCR
  • Novartis
  • Sinobioway Cell Therapy
  • Takara Bio
  • Unum Therapeutics
  • ZIOPHARM Oncology

第20章 结论

第21章 重要考察

第22章 附录1:表格形式的数据

第23章 附录2:企业·组织清单

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: RA100103

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2017 in the US alone. The World Health Organization states that the number of new cancer cases globally is expected to rise by 70% in the coming 20 years. Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Specifically, chemotherapy and radiation therapy are also associated with several side effects. Their non-specific nature has severe detrimental effects on the patients' quality of life.

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies. In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable therapeutic intervention. There are certain key characteristics that render T-cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 120 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups; in fact, during the last five years, over USD 8 billion has been invested by VC firms / other strategic investors. It is also worth highlighting that there have been more than 200 instances of collaborations between industry / academic stakeholders. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Encouraged by the recent approval of two CAR-T therapies, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), and a robust development pipeline, the T-cell immunotherapy market offers considerable promise to a number of industry stakeholders.

Synopsis:

The “T-Cell Immunotherapy Market, 2018-2030 (3rd edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms. Amongst other elements, the report features the following:

  • An analysis depicting prevalent and emerging trends related to T-cell immunotherapies as observed on the social media platform, Twitter. In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates.
  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of therapies, type of developer (industry / non-industry), phase of development, target therapeutic indications, key target antigens, source of T-cells (autologous and allogenic), and route of administration. In addition, we have provided an overview of the competitive landscape, key challenges and anticipated future trends associated with T-cell based therapies.
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available) , clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical CAR-T therapies based on generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • An analysis of the global CAR-T clinical trials registered between 2009 and 2018, highlighting the year wise trend and the distribution across different geographies.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others.
  • An analysis of the investments that have been made into companies that have proprietary products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs. It presents a detailed analysis of the approved / pipeline products in this domain, including information on the current phase of development, target therapeutic areas, type of T-cells used, and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely Kymriah and Yescarta.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes potential sales of T-cell immunotherapies that are currently marketed or are in late stages of development. Additionally, the chapter presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Over 480 T-cell therapies are being developed across various preclinical / clinical stages. Amongst these, CAR-T cell products are the most common (75%), followed by TCR (18%) and TIL (7%) based therapies. Two CAR-T products, namely Kymriah® (Novartis) and YESCARTA® (Gilead Sciences), were approved in 2017 for the treatment of acute lymphoblastic leukemia and large B-cell lymphoma, respectively.
  • 2. Around 63% of the pipeline therapies are undergoing clinical evaluation. Of the total clinical candidates, close to 40 therapies are in the late-stages of development (phase II and above) and are likely to enter the market in the next 5-10 years. Examples of late-stage therapies include bb2121 (bluebird bio / Celgene), IMCgp100 (Immunocore), MAGE A3 TCR (Kite Pharma), MB-CART19 (Miltenyi Biotec / Shanghai Children's Medical Center), NY-ESO-1 TCR (Adaptimmune Therapeutics / GSK), and LN-144 and LN-145 (Iovance Biotherapeutics).
  • 3. More than 80% of the products in the development pipeline are presently being developed to treat various hematological cancers and solid tumors, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia (58), non-Hodgkin's lymphoma (51), multiple myeloma (38), melanoma (37), chronic lymphocytic leukemia (31), lung cancer (29), pancreatic cancer (25), acute myeloid leukemia (24), hepatocellular carcinoma (24), glioblastoma (21), breast cancer (20) and ovarian cancer (20). Several therapy candidates are being developed for other therapeutic areas, such as autoimmune disorders and infectious diseases, as well.
  • 4. Amongst the various CAR-T therapies, 36% are designed to target the CD19 receptor. Other molecular targets that are being investigated include CD22, BCMA, Meso, CD20, GD2, CD30, HER1, HER2, EGFRvIII, MUC1, CD33, CD123, PSMA, GPC3, PD-L1, CEA, CD38, EPCAM and PSCA. Similarly, within the TCR segment, NY-ESO-1 is currently the most popular target antigen, followed by HBV, MART-1, p53, WT-1, MAGE A4, gp100, MAGE A3, HA-1 and MAGE A3/A6.
  • 5. The market is highly fragmented and characterized by the presence of over 115 start-ups, small pharma and big pharma firms. The key players involved in development of T-cell therapies (based on the number of candidate therapies in their respective pipelines) include Shanghai GeneChem, Juno Therapeutics, Kite Pharma, Marino Biotechnology, Cellular Biomedicine Group, Iovance Biotherapeutics, Adaptimmune Therapeutics, CARsgen Therapeutics, The Beijing Pregene Science and Technology Company, Merck, Intrexon, Shanghai Unicar-Therapy Bio-medicine Technology, Takara Bio and ZIOPHARM Oncology.
  • 6. Academic institutions are leading the innovation in this domain; many universities and research institutes have played a critical role in the discovery, design and development of novel CAR-T, TCR and TIL based therapies. Currently, around 55% of the pipeline therapies are being developed by academic players, either alone or in collaboration with industry players. The most active non-industry players (based upon the number of therapies under development) include the National Cancer Institute, Baylor College of Medicine, Shenzhen Geno-immune Medical Institute, University of Pennsylvania, Southwest Hospital, Chinese PLA General Hospital, Sun Yat-sen University, Fuda Cancer Hospital, Memorial Sloan Kettering Cancer Center, Peking University, Fred Hutchinson Cancer Research Center, Xinqiao Hospital of Chongqing, MD Anderson Cancer Center, and City of Hope Medical Center.
  • 7. In order to exploit the commercial potential of their respective assets, stakeholders in the industry have forged several synergistic partnerships. Overall, we identified 200 partnerships between various players (industry and academia) in the period January 2005-January 2018. Approximately 23% of the deals were R&D agreements. Other popular types of collaborations that were established in this domain include technology licensing agreements (18%), product development and commercialization agreements (16%), manufacturing agreements (9%), acquisitions (7%), clinical trial agreements (7%) and product licensing agreements (6%).
  • 8. Numerous contract manufacturing organizations (CMOs) with advanced capabilities have also emerged, offering services for manufacturing personalized T-cell based therapies. Examples of such CMOs include (in alphabetical order) Amsterdam Biotherapeutics Unit (AmBTU), apceth Biopharma, Atlantic Bio GMP, Brammer Bio, Cell and Gene Therapy Catapult, Cell Therapies, Cellular Therapeutics, EUFETS, MEDINET, MolMed, PCT, KBI Biopharma and WuXi AppTec.
  • 9. More than 150 funding instances, amounting to more than USD 8 billion worth of capital investment, have taken place in this field over the past few years. Venture capital investments contribute to over 29% of the total funding received by companies that are focused in this field. This is followed by other types of equity investments (24%), IPOs and post-IPO equity (16%), and grants (13%). Several big-ticket investments have recently taken place. For instance, Gilead Sciences announced acquisition of Kite Pharma for about USD 11.9 billion in August 2017 and Celgene acquired Juno Therapeutics in a deal valued at about USD 9 billion in March 2018.
  • 10. A variety of other types of T-cell immunotherapies, other than CAR-T, TCR and TIL, are also expected to emerge in the mid-long term. These include T-regulatory cell-based therapies, T-cell based vaccines, virus-driven T-cell therapies and next generation γδ immunotherapies. Companies such as TxCell, Caladrius Biosciences, Casebia Therapeutics, Cellenkos, Miltenyi Biotec, TRACT Therapeutics and Tmunity Therapeutics, are developing T-regulatory cell based therapies. Other players, namely Acer Therapeutics, Immunovative Therapies and TVAX Biomedical, are developing T-cell based vaccines for treating autoimmune disorders and various forms of cancer. Further, Atara Biotherapeutics, bluebird bio, Cell Medica, Shanghai iCELL Biotechnology and Tessa Therapeutics are working on the development of virus-driven T-cell therapies. Additionally, GammaCell Bio-Technologies is developing next generation γδ immunotherapies against various oncological indications, infectious diseases and autoimmune disorders.
  • 11. The T-cell immunotherapy market is projected to grow at an annualized rate of over 80% during the time period 2018-2030. Specifically, by 2030, close to 61% of the market is likely to be driven by CAR-T therapies. The market, in the long term, is likely to be driven by five indications, namely non-Hodgkin's lymphoma (45%), bladder cancer (13%), melanoma (11%), acute lymphoblastic leukemia (7%) and multiple myeloma (7%). Product candidates, such as Kymriah®, Yescarta®, JCAR017, ALT 801, NY-ESO-1 TCR and IMCgp100 are expected to achieve blockbuster status.
  • 12. In terms of geographical distribution, North America is the current hub and is likely to continue to dominate the market in the next decade. However, there is a general perception that, owing to the fact that more than 60% of the CAR-T trials are currently being conducted in China, the country is likely to grow at a relatively faster rate as compared to the developed regions.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies.

Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords and drug candidates, as observed on social media.

Chapter 5 provides information on around 500 T-cell immunotherapies that are currently in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of therapy (CAR-T, TCR and TIL), type of developer(s), phase of development, target therapeutic areas and indications, key target antigens, source of T-cells (autologous and allogenic) and route of administration. Further, the chapter identifies the most active players (in terms of number of pipeline candidates) and features a logo landscape representation, highlighting product developers in North America, Europe and the Asia Pacific region.

Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. Further, the chapter includes an analysis on global CAR-T trials registered between 2009 to 2018, featuring the year wise trend and distribution of CAR-T trials across different geographies. In addition, it includes comprehensive analysis of more than 400 clinical trials that have been completed or are currently being conducted to evaluate T-cell immunotherapies with respect to the type of T-cell immunotherapy (CAR-T, TCR and TIL), phase of development, patient segment, and type of therapy (monotherapy and combination therapy).

Chapter 7 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to ongoing research in this field. It features a discussion on the molecular targets that are currently under investigation and the current challenges (such as toxicity issues) that are associated with this segment. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain. This section also includes detailed profiles of the approved / late stage CAR-T cell therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.

Chapter 8 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It features a discussion on the molecular targets that are currently under investigation and the current challenges (such as toxicity issues) that are associated with this segment. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. This section also includes detailed profiles of the late stage TCR therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.

Chapter 9 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. This section also includes detailed profiles of the late stage TIL therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.

Chapter 10 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 11 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. It features brief profiles of some of the key technologies as well. Each profile contains details on the various pipeline molecules that have been / are being developed using the technology, its advantages and the associated partnerships.

Chapter 12 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others, the companies involved, the type of therapy and prominent product candidates involved.

Chapter 13 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2017, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 14 features details of other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on the current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 16 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 17 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma).

Chapter 18 highlights the key promotional strategies that are being implemented by the developers of the marketed products, Kymriah and Yescarta. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 19 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 20 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 21 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Enkhtsetseg Purev (Assistant Professor Of Medicine, University Of Colorado), Miguel Forte (Chief Operating Officer, TxCell), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Tim Oldham (Chief Executive Officer, Cell Therapies), Victor Lietao Li (Co-Founder & Chief Executive Officer, Lion TCR), Vincent Brichard (Vice President, Immuno-Oncology, Celyad) and Xian-Bao Zhan (Professor Of Medicine and Director, Department Of Oncology, Changhai Hospital).

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Immunotherapy, an Emerging Therapeutic Option
  • 3.4. Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
      • 3.5.1.1. Active Immunotherapy
      • 3.5.1.2. Passive Immunotherapy
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Oncolytic Virus Therapy
      • 3.5.4.5. Therapeutic Cancer Vaccines
      • 3.5.4.6. Cell-based Therapies
  • 3.6. Historical Evolution of T-Cell Immunotherapies
  • 3.7. Key Considerations of T-Cell Immunotherapies
  • 3.8. Strategies Employed for Redirection of T-Cells
  • 3.9. Manufacturing of Engineered T-Cells
  • 3.10. T-Cell Transduction / Transfection Methods
    • 3.10.1. Retroviral Vectors
    • 3.10.2. Lentiviral Vectors
    • 3.10.3. Non-viral Transfection Methods
  • 3.11. Therapeutic Areas Targeted by T-Cell Immunotherapies
  • 3.12. Key Challenges of T-Cell Immunotherapies

4. EMERGING TRENDS ON SOCIAL MEDIA

  • 4.1. Chapter Overview
  • 4.2. Trends on Twitter
    • 4.2.1. T-Cell Immunotherapies: Yearly Trends on Twitter
    • 4.2.2. T-Cell Immunotherapies: Popular Keywords on Twitter
    • 4.2.3. T-Cell Immunotherapies: Most Popular Drugs on Twitter

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.3. T-Cell Immunotherapies: A Promising Pipeline
    • 5.3.1. T-Cell Immunotherapies: Distribution by Type of Product
    • 5.3.2. T-Cell Immunotherapies: Distribution by Type of Developer
    • 5.3.3. T-Cell Immunotherapies: Distribution by Phase of Development
    • 5.3.4. T-Cell Immunotherapies: Target Oncological Indications
      • 5.3.4.1. CAR-T Immunotherapies: Popular Target Indications
      • 5.3.4.2. TCR Immunotherapies: Popular Target Indications
      • 5.3.4.3. TIL Immunotherapies: Popular Target Indications
    • 5.3.5. T-Cell Immunotherapies: Popular Target Antigens for CAR-T and TCR Therapies
    • 5.3.6. T-Cell Immunotherapies: Distribution by Source of T-Cells
    • 5.3.7. T-Cell Immunotherapies: Distribution by Route of Administration
    • 5.3.8. T-Cell Immunotherapies: Key Industry Players
    • 5.3.9. T-Cell Immunotherapies: Key Non-Industry Players

6. KEY INSIGHTS

  • 6.1. Chapter Overview
  • 6.2. T-Cell Immunotherapies: Analysis by Popularity of Target Antigens
    • 6.2.1. Hematological Cancer: Popular Targets
      • 6.2.1.1. CD19 CAR-T Immunotherapies: Competitive Landscape
      • 6.2.1.2. CD19 CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
      • 6.2.1.3. BCMA CAR-T Immunotherapies: Competitive Landscape
      • 6.2.1.4. BCMA CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
    • 6.2.2. Solid Tumors: Popular Targets
      • 6.2.2.1. Meso CAR-T Immunotherapies: Competitive Landscape
      • 6.2.2.2. Meso CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
      • 6.2.2.3. GD2 CAR-T Immunotherapies: Competitive Landscape
      • 6.2.2.4. GD2 CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Therapies
  • 6.3. T-Cell Immunotherapies: CAR-T Clinical Trial Trends, Pre-2012-2018
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Geographical Analysis by Number of Registered Trials
  • 6.4. T-Cell Immunotherapies: Clinical Trial Overview
    • 6.4.1. Clinical Trial Analysis: Distribution by Type of Product
    • 6.4.2. Clinical Trial Analysis: Distribution by Phase of Development
    • 6.4.3. Clinical Trial Analysis: Distribution by Patient Segment
    • 6.4.4. Clinical Trial Analysis: Distribution by Type of Therapy

7. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY

  • 7.1. Introduction
  • 7.2. History of Development
  • 7.3. Key Opinion Leaders
  • 7.4. Anatomical Layout of Chimeric Antigen Receptor
  • 7.5. CAR-T Construction Analysis
    • 7.5.1. Analysis by Generation of CAR-T Therapies
    • 7.5.2. Analysis by Type of scFv Antibody
    • 7.5.3. Analysis by Type of Vector
    • 7.5.4. Analysis by Type of Co-Stimulatory Domain(s)
  • 7.6. Development of Chimeric Antigen Receptors
  • 7.7. Development of CAR-T Cells
  • 7.8. Universal CAR-Ts
  • 7.9. Route of Administration
  • 7.10. Toxicity Concerns
    • 7.10.1. Cytokine Release Syndrome (CRS)
    • 7.10.2. On-Target Off-Target Toxicity
    • 7.10.3. Encephalopathy and B-Cell Aplasia
    • 7.10.4. Neurological Toxicity
    • 7.10.5. Anaphylaxis
    • 7.10.6. Insertional Oncogenesis
    • 7.10.7. Graft Versus Host Disease (GVHD)
  • 7.11. Management of Toxicity Issues
    • 7.11.1. Pharmacological Immunosuppression
    • 7.11.2. Target Selection
    • 7.11.3. Cell Persistence
    • 7.11.4. Elimination Genes
    • 7.11.5. Receptor Expression
  • 7.12. CD19: An Attractive Target
  • 7.13. Other Targets
  • 7.14. Challenges Associated with CAR-T Therapies
    • 7.14.1. Competitive Risks
    • 7.14.2. Clinical Risks
    • 7.14.3. Regulatory Risks
    • 7.14.4. Commercial Risks
  • 7.15. Kymriah® / Tisagenlecleucel / CTL019 (Novartis)
    • 7.15.1. Therapy Overview
    • 7.15.2. History of Development
    • 7.15.3. Current Development Status
    • 7.15.4. Key Clinical Trial Results
    • 7.15.5. Dosage Regimen, Price and Manufacturing
  • 7.16. Yescarta® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
    • 7.16.1. Therapy Overview
    • 7.16.2. Current Development Status
    • 7.16.3. Key Clinical Trial Results
    • 7.16.4. Dosage Regimen, Price and Manufacturing
    • 7.16.5. Next Generation eACT CAR Candidates
  • 7.17. JCAR (Juno Therapeutics)
    • 7.17.1. Therapy Overview
    • 7.17.2. CAR-T Design
    • 7.17.3. Current Development Status
    • 7.17.4. Key Clinical Trial Results
      • 7.17.4.1. JCAR014
      • 7.17.4.2. JCAR017
      • 7.17.4.3. JCAR018
    • 7.17.5. Dosage Regimen and Manufacturing
  • 7.18. CAR-T Series (Cellular Biomedicine Group)
    • 7.18.1. Therapy Overview
    • 7.18.2. History of Development
    • 7.18.3. Current Development Status
    • 7.18.4. Key Clinical Trial Results
      • 7.18.4.1. CBM-EGFR.1
      • 7.18.4.2. CBM-C19.1
      • 7.18.4.1. CBM-C20.1
      • 7.18.4.2. CBM-C30.1
    • 7.18.5. Dosage Regimen and Manufacturing
    • 7.18.6 Patent Portfolio
  • 7.19. CD19 CAR (Takara Bio)
    • 7.19.1. Therapy Overview
    • 7.19.2. Current Development Status
    • 7.19.3. Key Clinical Trial Results
    • 7.19.4. Dosage Regimen and Manufacturing
  • 7.20. Dual Targeting CAR-T Cell Therapies (Autolus)
    • 7.20.1. Therapy Overview
    • 7.20.2. Current Development Status
    • 7.20.3. Key Clinical Trial Results
    • 7.20.4. Dosage Regimen and Manufacturing
  • 7.21. CAR-T Therapies (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
    • 7.21.1. Therapy Overview
    • 7.21.2. Current Development Status
    • 7.21.3. Key Clinical Trial Results
    • 7.21.4. Dosage Regimen and Manufacturing

8. T-CELL RECEPTOR (TCR) BASED THERAPIES

  • 8.1. Chapter Overview
  • 8.2. Structure of the T-Cell Receptor
  • 8.3. Differences Between CAR and TCR
  • 8.4. History of Development
  • 8.5. Mechanism of Action
  • 8.6. Key Opinion Leaders
  • 8.7. Safety Concerns
    • 8.7.1. Insertional Mutagenesis
    • 8.7.2. On-Target, Off-Tumor Toxicity and Cross-Reactivity
    • 8.7.3. TCR Mismatch Pairing
  • 8.8. Prerequisites for Antigen-Specific T-Cell Receptors
  • 8.9. Strategies to Enhance Antitumor Efficacy
    • 8.9.1. Affinity Enhanced TCRs
    • 8.9.2. Soluble TCR Based Biologics
  • 8.10. SPEAR® T-Cells (Adaptimmune)
    • 8.10.1. Therapy Overview
      • 8.10.1.1. NY-ESO SPEAR T-Cell
      • 8.10.1.2. Mage-A10 T-Cell Therapy
      • 8.10.1.3. AFP T-Cell Therapy
      • 8.10.1.4. Mage-A4 T-Cell Therapy
    • 8.10.2. History of Development
    • 8.10.3. SPEAR T-Cells Technology Platform
    • 8.10.4. Current Development Status
    • 8.10.5. Key Clinical Trial Results
    • 8.10.6. Dosage Regimen and Manufacturing
  • 8.11. ALT-801 (Altor BioScience)
    • 8.11.1. Therapy Overview
    • 8.11.2. History of Development
    • 8.11.3. Current Development Status
    • 8.11.4. Key Clinical Trial Results
    • 8.11.5. Dosage Regimen
    • 8.11.6. Patent Portfolio
  • 8.12. IMCgp100 (Immunocore)
    • 8.12.1. Therapy Overview
    • 8.12.2. Current Development Status
    • 8.12.3. Key Clinical Trial Results
    • 8.12.4. Dosage Regimen and Manufacturing
  • 8.13. JTCR016 (Juno Therapeutics)
    • 8.13.1. Therapy Overview
    • 8.13.2. Current Development Status
    • 8.13.3. Key Clinical Results
    • 8.13.4. Dosage Regimen
  • 8.14. CMD-602 / WT1 TCR Therapy (Cell Medica)
    • 8.14.1. Therapy Overview
    • 8.14.2. History of Development
    • 8.14.3. Current Development Status
    • 8.14.4. Key Clinical Trial Results
    • 8.14.5. Dosage Regimen and Manufacturing
  • 8.15. TBI-1301 (Takara Bio)
    • 8.15.1. Therapy Overview
    • 8.15.2. Current Development Status
    • 8.15.3. Key Clinical Trial Results
    • 8.15.4. Dosage Regimen and Manufacturing

9. TUMOR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES

  • 9.1. Chapter Overview
  • 9.2. History of Development
  • 9.3. Key Opinion Leaders
  • 9.4. Strategies to Enhance Efficacy
  • 9.5. Prognostic Applications
  • 9.6. Manufacturing Process
  • 9.7. Autologous TIL Therapies (Iovance Biotherapeutics)
    • 9.7.1. Therapy Overview
    • 9.7.2. Current Development Status
      • 9.7.2.1. LN-144
      • 9.7.2.2. LN-145
    • 9.7.3. Key Clinical Trial Results
    • 9.7.4. Dosage Regimen and Manufacturing
    • 9.7.5. Patent Portfolio
  • 9.8. TIL (Nantes University Hospital)
    • 9.8.1. Therapy Overview
    • 9.8.2. Current Development Status
    • 9.8.3. Key Clinical Trial Results
    • 9.8.4. Dosage Regimen and Manufacturing
  • 9.9. TIL (Netherlands Cancer Institute)
    • 9.9.1. Therapy Overview
    • 9.9.2. Current Development Status
    • 9.9.3. Key Clinical Trial Results
    • 9.9.4. Dosage Regimen and Manufacturing

10. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES

  • 10.1. Chapter Overview
  • 10.2. Hematological Malignancies
    • 10.2.1. Leukemia and Lymphoma
      • 10.2.1.1. Leukemia: Introduction and Epidemiology
      • 10.2.1.1.1. Acute Myeloid Leukemia (AML)
      • 10.2.1.1.2. Chronic Myeloid Leukemia (CML)
      • 10.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
      • 10.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
      • 10.2.1.2. Lymphoma: Introduction and Epidemiology
      • 10.2.1.3. Current Treatment Landscape
      • 10.2.1.3.1. Targeted Therapies
      • 10.2.1.4. T-Cell Immunotherapy and Research Landscape
      • 10.2.1.4.1. CAR-T Therapies and Leukemia / Lymphoma
      • 10.2.1.4.2. TCR Therapies and Leukemia / Lymphoma
    • 10.2.2. Multiple Myeloma
      • 10.2.2.1. Introduction and Epidemiology
      • 10.2.2.2. Current Treatment Landscape
      • 10.2.2.3. T-Cell Immunotherapy and Research Landscape
  • 10.3. Solid Tumors
    • 10.3.1. Metastatic Melanoma
      • 10.3.1.1. Introduction and Epidemiology
      • 10.3.1.2. Current Treatment Landscape
      • 10.3.1.3. T-Cell Immunotherapy and Research Landscape
      • 10.3.1.3.1. TILs and Metastatic Melanoma
      • 10.3.1.3.2. TCRs and Metastatic Melanoma
      • 10.3.1.3.3. CAR-Ts and Metastatic Melanoma
    • 10.3.2. Lung Cancer
      • 10.3.2.1. Introduction and Epidemiology
      • 10.3.2.2. Current Treatment Landscape
      • 10.3.2.3. T-Cell Immunotherapy and Research Landscape
    • 10.3.3. Bladder Cancer
      • 10.3.3.1. Introduction and Epidemiology
      • 10.3.3.2. Current Treatment Landscape
      • 10.3.3.3. T-Cell Immunotherapy and Research Landscape
    • 10.3.4. Kidney Cancer
      • 10.3.4.1. Introduction and Epidemiology
      • 10.3.4.2. Current Treatment Landscape
      • 10.3.4.3. T-Cell Immunotherapy and Research Landscape
    • 10.3.5. Ovarian Cancer
      • 10.3.5.1. Introduction and Epidemiology
      • 10.3.5.2. Current Treatment Landscape
      • 10.3.5.3. T-Cell Immunotherapy and Research Landscape
      • 10.3.5.3.1. CAR-Ts and Ovarian Cancer
      • 10.3.5.3.2. TCRs and Ovarian Cancer
      • 10.3.5.3.3. TILs and Ovarian Cancer
    • 10.3.6. Breast Cancer
      • 10.3.6.1. Introduction and Epidemiology
      • 10.3.6.2. Current Treatment Landscape
      • 10.3.6.3. T-Cell Immunotherapy and Research Landscape
      • 10.3.6.3.1. CAR-Ts and Breast Cancer
      • 10.3.6.3.2. TILs and Breast Cancer

11. EMERGING TECHNOLOGIES

  • 11.1. Chapter Overview
  • 11.2. Genome Editing Technologies
    • 11.2.1. Technology Overview
    • 11.2.2. Applications
    • 11.2.3. Emerging Technology Platforms used in T-Cell Therapies
      • 11.2.3.1. CRISPR / Cas9 System
      • 11.2.3.1.1. Key Components and Function
      • 11.2.3.1.2. Mechanism of Action
      • 11.2.3.1.3. Targeting Efficiency and Challenges
      • 11.2.3.1.4. Next-GEN CRISPR Technology
      • 11.2.3.1.5. Technology Providers
        • 11.2.3.1.5.1. Editas Medicine
        • 11.2.3.1.5.2. Intellia Therapeutics
        • 11.2.3.1.5.3. CRISPR Therapeutics
      • 11.2.3.2. TALENs
      • 11.2.3.2.1. Key Components and Function
      • 11.2.3.2.2. Mechanism of Action
      • 11.2.3.2.3. Advantages and Challenges
      • 11.2.3.2.4. Technology Providers
        • 11.2.3.2.4.1. Cellectis
        • 11.2.3.2.4.2. Editas Medicine
      • 11.2.3.3. megaTAL
      • 11.2.3.3.1. Technology Providers
        • 11.2.3.3.1.1. bluebird bio
      • 11.2.3.4. Zinc Finger Nuclease
      • 11.2.3.4.1. Technology Providers
        • 11.2.3.4.1.1. Sangamo Therapeutics
  • 11.3. Designing T-Cell Therapies with Improved Characteristics
    • 11.3.1. Technologies for Targeting Multiple Cancers
      • 11.3.1.1. Antibody Coupled T-Cell Receptor (Unum Therapeutics)
      • 11.3.1.2. NKR-T Platform (Celyad)
    • 11.3.2. Technologies for Improved Safety
      • 11.3.2.1. Armored CAR and EGFRt Technology (Juno Therapeutics)
      • 11.3.2.2. RheoSwitch Therapeutic System (Intrexon)
      • 11.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals)
      • 11.3.2.3.1. CaspaCIDe Technology
      • 11.3.2.3.2. CIDeCAR Technology
      • 11.3.2.3.3. GoCAR-T Technology
      • 11.3.2.4. On-Off Switch, Multiple Companies
      • 11.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
      • 11.3.2.4.2. On-Off Switch (Theravectys)
      • 11.3.2.5. Other Technologies to Improve CAR-T Safety
      • 11.3.2.6. Allogeneic Technologies
      • 11.3.2.6.1. CIK CAR-T Cells (Formula Pharmaceuticals)
      • 11.3.2.6.2. Allogeneic Platform (Celyad)
      • 11.3.2.6.3. Allogeneic Platform (Cellectis)

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Types of Partnership Models
  • 12.3. T-Cell Immunotherapy Market: Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership Model
    • 12.3.3. Analysis by Number of Partnerships (Most Active Industry Players)
    • 12.3.4. Analysis by Number of Partnerships (Most Active Non-Industry Players)
    • 12.3.5. Analysis by Type of Product
    • 12.3.6. Analysis by Individual Products

13. FUNDING AND INVESTMENT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Types of Funding
  • 13.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
    • 13.3.1. Analysis by Number of Funding Instances
    • 13.3.2. Analysis by Amount Invested
    • 13.3.3. Analysis by Type of Funding
    • 13.3.4. Analysis by Key Players

14. OTHER T-CELL IMMUNOTHERAPIES

  • 14.1. Chapter Overview
  • 14.2. Other T-Cell Immunotherapies
    • 14.2.1. Distribution by Phase of Development
    • 14.2.2. Distribution by Target Therapeutic Area
    • 14.2.3. Distribution by Type of Cells
    • 14.2.4. Distribution by Source of T-Cells
  • 14.3. Treg Cell Therapy
    • 14.3.1. Caladrius Biosciences
    • 14.3.2. TxCell
    • 14.3.3. TRACT Therapeutics
    • 14.3.4. Cellenkos
    • 14.3.5. Other Companies
  • 14.4. T-Cell-based Vaccines
    • 14.4.1. Immunovative Therapies
    • 14.4.2. Acer Therapeutics
    • 14.4.3. TVAX Biomedical
  • 14.5. Virus-Driven T-Cell Therapies
    • 14.5.1. Atara Biotherapeutics
    • 14.5.2. Cell Medica
    • 14.5.3. Tessa Therapeutics
  • 14.6. Fucosylation Technology Platform
    • 14.6.1. Targazyme
  • 14.7. PD-1 Knockout Engineered T-Cell Therapy
    • 14.7.1. Chengdu MedGenCell
    • 14.7.2. Anhui Kedgene Biotechnology
    • 14.7.3. Cell Biotech
  • 14.8. TAC-T Cell Therapy
    • 14.8.1. Triumvira
  • 14.9. Gama Delta T-Cell Immunotherapy
    • 14.9.1. GammaCell Bio-Technologies

15. CASE STUDY: CELL THERAPY MANUFACTURING

  • 15.1. Chapter Overview
  • 15.2. Introduction
  • 15.3. Key Challenges
  • 15.4. Current Trends
    • 15.4.1. Companies with In-House Capabilities
    • 15.4.2. Contract Manufacturers
  • 15.5. Key Considerations for a Manufacturing Site
  • 15.6. Regulatory Landscape

16. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Factors Contributing Towards High Price Tags of Cell / Gene Therapies
  • 16.3. Pricing Models for T-Cell Immunotherapies
    • 16.3.1. On the Basis of Associated Costs
    • 16.3.2. On the Basis of Competition
    • 16.3.3. On the Basis of Patient Segment
    • 16.3.4. On the Basis of Experts Opinions
  • 16.4. Reimbursement Considerations for T-Cell Immunotherapies
    • 16.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy

17. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Scope and Limitations
  • 17.3. Forecast Methodology
  • 17.4. Overall T-Cell Immunotherapy Market, 2018-2030
    • 17.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
    • 17.4.2. T-Cell Immunotherapy Market: Distribution by Geography
    • 17.4.3. T-Cell Immunotherapy Market: Distribution by Target Indications
  • 17.5. T-Cell Immunotherapy Market: Product-Wise Sales Forecasts
    • 17.5.1. Overall CAR-T Therapy Market
      • 17.5.1.1. Kymriah (Novartis)
        • 17.5.1.1.1. Target Population
        • 17.5.1.1.2. Sales Forecast
      • 17.5.1.2. Yescarta (Gilead Sciences)
        • 17.5.1.2.1. Target Population
        • 17.5.1.2.2. Sales Forecast
      • 17.5.1.3. CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
        • 17.5.1.3.1. Target Population
        • 17.5.1.3.2. Sales Forecast
      • 17.5.1.4. GPC3 CAR-T (Shanghai GeneChem)
        • 17.5.1.4.1. Target Population
        • 17.5.1.4.2. Sales Forecast
      • 17.5.1.5. TBI-1501 / CD19 CAR-T (Takara Bio / Jichi Medical University)
        • 17.5.1.5.1. Target Population
        • 17.5.1.5.2. Sales Forecast
      • 17.5.1.6. JCAR017 (Juno Therapeutics / Celgene)
        • 17.5.1.6.1. Target Population
        • 17.5.1.6.2. Sales Forecast
      • 17.5.1.7. MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center)
        • 17.5.1.7.1. Target Population
        • 17.5.1.7.2. Sales Forecast
      • 17.5.1.8. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
        • 17.5.1.8.1. Target Population
        • 17.5.1.8.2. Sales Forecast
      • 17.5.1.9. PCAR-019 (PersonGen BioTherapeutics)
        • 17.5.1.9.1. Target Population
        • 17.5.1.9.2. Sales Forecast
      • 17.5.1.10. AUTO2 (Autolus)
        • 17.5.1.10.1. Target Population
        • 17.5.1.10.2. Sales Forecast
      • 17.5.1.11. AUTO3 (Autolus)
        • 17.5.1.11.1. Target Population
        • 17.5.1.11.2. Sales Forecast
      • 17.5.1.12. BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital)
        • 17.5.1.12.1. Target Population
        • 17.5.1.12.2. Sales Forecast
      • 17.5.1.13. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology / Henan Cancer Hospital)
        • 17.5.1.13.1. Target Population
        • 17.5.1.13.2. Sales Forecast
      • 17.5.1.14. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University)
        • 17.5.1.14.1. Target Population
        • 17.5.1.14.2. Sales Forecast
      • 17.5.1.15. LCAR-B38M CAR-T (Nanjing Legend Biotech)
        • 17.5.1.15.1. Target Population
        • 17.5.1.15.2. Sales Forecast
      • 17.5.1.16. CD19 CAR-T (Shanghai Bioray Laboratory)
        • 17.5.1.16.1. Target Population
        • 17.5.1.16.2. Sales Forecast
      • 17.5.1.17. bb2121 (Celgene / bluebird bio)
        • 17.5.1.17.1. Target Population
        • 17.5.1.17.2. Sales Forecast
    • 17.5.2. Overall TCR Therapy Market
      • 17.5.2.1. IMCgp100 (Immunocore)
        • 17.5.2.1.1. Target Population
        • 17.5.2.1.2. Sales Forecast
      • 17.5.2.2. NY-ESO-1 TCR (Adaptimmune / GSK)
        • 17.5.2.2.1. Target Population
        • 17.5.2.2.2. Sales Forecast
      • 17.5.2.3. JTCR016 (Juno Therapeutics)
        • 17.5.2.3.1. Target Population
        • 17.5.2.3.2. Sales Forecast
      • 17.5.2.4. LTCR-H1-2 (Lion TCR, Agency for Science, Technology and Research, Third Affiliated Hospital, Sun Yat-Sen University)
        • 17.5.2.4.1. Target Population
        • 17.5.2.4.2. Sales Forecast
      • 17.5.2.5. ALT 801 (Altor Bioscience)
        • 17.5.2.5.1. Target Population
        • 17.5.2.5.2. Sales Forecast
      • 17.5.2.6. TBI-1301 (Takara Bio)
        • 17.5.2.6.1. Target Population
        • 17.5.2.6.2. Sales Forecast
    • 17.5.3. Overall TIL Therapy Market
      • 17.5.3.1. TIL (Nantes University Hospital)
        • 17.5.3.1.1. Target Population
        • 17.5.3.1.2. Sales Forecast
      • 17.5.3.2. TIL (Netherlands Cancer Institute)
        • 17.5.3.2.1. Target Population
        • 17.5.3.2.2. Sales Forecast
      • 17.5.3.3. LN-144 (Iovance Biotherapeutics)
        • 17.5.3.3.1. Target Population
        • 17.5.3.3.2. Sales Forecast
      • 17.5.3.4. LN-145 (Iovance Biotherapeutics)
        • 17.5.3.4.1. Target Population
        • 17.5.3.4.2. Sales Forecast

18. PROMOTIONAL ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Channels Used for Promotional Campaigns
  • 18.3. Summary of Product Website Analysis
  • 18.4. Summary of Patient Support Services and Informative Downloads
  • 18.5. Kymriah®: Promotional Analysis
    • 18.5.1. Drug Overview
    • 18.5.2. Product Website Analysis
      • 18.5.2.1. Messages for Healthcare Professionals
      • 18.5.2.2. Messages for Patients
    • 18.5.3. Patient Support Services and Informative Downloads
    • 18.5.4. Other Promotional Activities
      • 18.5.4.1. Presence in Conferences
  • 18.6. Yescarta®: Promotional Analysis
    • 18.6.1. Drug Overview
    • 18.6.2. Product Website Analysis
      • 18.6.2.1. Messages for Patients and Caregivers
      • 18.6.2.2. Patient Support Services and Informative Downloads
    • 18.6.3. Other Promotional Activities
      • 18.6.3.1. Presence in Conferences

19. COMPANY PROFILES

  • 19.1. Chapter Overview
  • 19.2. Adaptimmune Therapeutics
  • 19.3. Autolus
  • 19.4. bluebird bio
  • 19.5. CARsgen Therapeutics
  • 19.6. Celgene
  • 19.7. Cell Medica
  • 19.8. Cellectis
  • 19.9. Cellular Biomedicine Group
  • 19.10. Immunocore
  • 19.11. Innovative Cellular Therapeutics
  • 19.12. Iovance Biotherapeutics
  • 19.13. Kite Pharma (A Gilead Sciences Company)
  • 19.14. Lion TCR
  • 19.15. Novartis
  • 19.16. Sinobioway Cell Therapy
  • 19.17. Takara Bio
  • 19.18. Unum Therapeutics
  • 19.19. ZIOPHARM Oncology

20. CONCLUSION

  • 20.1. With Steady Growth in the Development Pipeline, T-Cell based Therapies have Emerged as a Promising Segment of the Immunotherapy Market
  • 20.2. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
  • 20.3. The Competitive Landscape Features a Mix of Established Players and Start-ups, with Academic Institutes Spearheading Early-stage Development Activities
  • 20.4. A Number of Novel Technology Platforms have also Emerged as Vital Enablers of Growth in this Market
  • 20.5. Multiple Novel Types of Immunotherapies, other than CAR-T, TCR and TIL, are also Expected to Enter the Market in the Mid-Long Term
  • 20.6. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of the Lucrative Future Potential
  • 20.7. The Premium Pricing of these Therapies Necessitate Appropriate Reimbursement and Promotional Strategies to Guarantee Commercial Success
  • 20.8. Driven by the Approval of Two CAR-T Therapies and Encouraging Results of Late-stage Candidates, the Market is Expected to Grow Significantly in the Long Term

21. EXECUTIVE INSIGHTS

  • 21.1. Chapter Overview
  • 21.2. Cell Therapies
    • 21.2.1. Company Snapshot
    • 21.2.2. Interview Transcript: Tim Oldham, Chief Executive Officer
  • 21.3. Celyad
    • 21.3.1. Company Snapshot
    • 21.3.2. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
  • 21.4. Changhai Hospital
    • 21.4.1. Company Snapshot
    • 21.4.2. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
  • 21.5. Iovance Biotherapeutics
    • 21.5.1. Company Snapshot
    • 21.5.2. Interview Transcript: Peter Ho, Director, Process Development
  • 21.6. Kite Pharma
    • 21.6.1. Company Snapshot
    • 21.6.2. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
  • 21.7. Lion TCR
    • 21.7.1. Company Snapshot
    • 21.7.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
  • 21.8. Theravectys
    • 21.8.1. Company Snapshot
    • 21.8.2. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
  • 21.9. TxCell
    • 21.9.1. Company Snapshot
    • 21.9.2. Interview Transcript: Miguel Forte, Chief Operating Officer
  • 21.10. University of Colorado
    • 21.10.1. Company Snapshot
    • 21.10.2. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
  • 21.11. Waisman Biomanufacturing
    • 21.11.1. Company Snapshot
  • 21.1.2. Interview Transcript: Brian Dattilo, Manager of Business Development

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES

List of Figures

  • Figure 3.2: Difference between Active and Passive Immunotherapies
  • Figure 3.3: Difference between Specific and Non-Specific Immunotherapies
  • Figure 3.4: 3Es of the Immune System
  • Figure 3.5: Strategies Employed for the Redirection of T-Cells
  • Figure 3.6: T-Cell Manufacturing: General Procedure
  • Figure 3.7: T-Cell Immunotherapies: Targeted Therapeutic Areas
  • Figure 3.8: T-Cell Immunotherapies: Key Challenges
  • Figure 4.1: T-Cell Immunotherapy Social Media Analysis: Twitter Trends, 2012-2017
  • Figure 4.2: T-Cell Immunotherapy Social Media Analysis: Popular Keywords on Twitter, 2012-2017
  • Figure 4.3: T-Cell Immunotherapy Social Media Analysis: Twitter, Most Popular Candidates, 2012-2017
  • Figure 5.1: T-Cell Immunotherapy Pipeline: Distribution by Type of Product
  • Figure 5.2: T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
  • Figure 5.3: T-Cell Immunotherapy Pipeline: Distribution by Type of Developer and Type of Product
  • Figure 5.4: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
  • Figure 5.5: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development and Type of Product
  • Figure 5.6: T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
  • Figure 5.7: T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area and Type of Product
  • Figure 5.8: T-Cell Immunotherapy Pipeline: Popular Target Indications
  • Figure 5.9: CAR-T Immunotherapy Pipeline: Popular Target Indications
  • Figure 5.10: TCR Immunotherapy Pipeline: Popular Target Indications
  • Figure 5.11: TIL Immunotherapy Pipeline: Popular Target Indications
  • Figure 5.12: CAR-T Immunotherapy Pipeline: Distribution by Target Antigen
  • Figure 5.13: TCR Immunotherapy Pipeline: Distribution by Target Antigen
  • Figure 5.14: T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells
  • Figure 5.15: T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells and Type of Product
  • Figure 5.16: T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
  • Figure 5.17: T-Cell Immunotherapy Pipeline: Distribution by Route of Administration
  • Figure 5.18: T-Cell Immunotherapy Pipeline: and Type of Product
  • Figure 5.19: T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
  • Figure 5.20: T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
  • Figure 5.21: T-Cell Immunotherapy Pipeline: Active Non-Industry Players in Clinical Development
  • Figure 5.22: T-Cell Immunotherapy Pipeline: Active Non-Industry Players in Preclinical Development
  • Figure 6.1: T-Cell Immunotherapies: Popular Targets in Hematological Cancer
  • Figure 6.2: T-Cell Immunotherapies: Popular Targets in Solid Tumor
  • Figure 6.3: CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
  • Figure 6.4: CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
  • Figure 6.5: T-Cell Immunotherapies: Distribution of Clinical Trials by Type of Product
  • Figure 6.6: T-Cell Immunotherapies: Distribution of Clinical Trials by Phase of Development
  • Figure 6.7: T-Cell Immunotherapies: Distribution of Clinical Trial by Phase of Development Across CAR-T, TCR and TIL
  • Figure 6.8: T-Cell Immunotherapies: Distribution of Clinical Trials by Patient Segment
  • Figure 6.9: T-Cell Immunotherapies: Distribution of Clinical Trial by Patient Segment and Type of Product
  • Figure 6.10: T-Cell Immunotherapies: Distribution of Clinical Trials by Type of Therapy
  • Figure 6.11: T-Cell Immunotherapies: Distribution of Clinical Trial by Type of Therapy and Type of Product
  • Figure 7.1: Historical Timeline: Development of CAR-T cells
  • Figure 7.2: CAR-T Cell Therapy: Geographical Distribution of Key Opinion Leaders
  • Figure 7.3: CAR-T Therapy: Prominent Key Opinion Leaders
  • Figure 7.4: CAR-T: Structure and Domains
  • Figure 7.5: CAR-Construction: Distribution by Generation of CAR-T Therapies
  • Figure 7.6: CAR-Construction: Distribution by Type scFv Used in CAR-T Therapies
  • Figure 7.7: CAR-Construction: Distribution by Type of Vector
  • Figure 7.8: CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
  • Figure 7.9: CAR-T: CAR Generations Layout
  • Figure 7.10: Development of CAR-T Cells
  • Figure 7.11: Challenges Associated with CAR-T Therapy
  • Figure 7.12: Kymriah: Industry Sponsored Clinical Trial Design
  • Figure 7.13: Kymriah: Non-Industry Sponsored Clinical Trial Design
  • Figure 7.14: JCAR Series: Industry Sponsored Clinical Trial Design
  • Figure 7.15: JCAR Series: Non-Industry Sponsored Clinical Trial Design
  • Figure 7.16: Yescarta: Clinical Trial Design
  • Figure 7.17: Manufacturing of CD19 CAR-T Cells: Process Comparison
  • Figure 7.18: Cellular Biomedicine's CAR-T Series: Clinical Trial Design
  • Figure 7.19: Takara Bio's CD19 CAR-T: Clinical Trial Design
  • Figure 7.20: Autolus's Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
  • Figure 7.21: Sinobioway Cell Therapy's Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
  • Figure 8.1: TCR Cell Therapy: Geographical Distribution of Key Opinion Leaders
  • Figure 8.2: TCR Therapy: Prominent Key Opinion Leaders
  • Figure 8.3: TCR Cell Therapy: Development Process
  • Figure 8.4: NY-ESO TCR: Industry Sponsored Clinical Trial Design
  • Figure 8.5: MAGE A-10 TCR: Industry Sponsored Clinical Trial Design
  • Figure 8.6: MAGE A-4 TCR: Industry Sponsored Clinical Trial Design
  • Figure 8.7: AFP TCR: Industry Sponsored Clinical Trial Design
  • Figure 8.8: ALT-801: Clinical Trial Design
  • Figure 8.9: IMCgp100: Clinical Trial Design
  • Figure 8.10: JTCR016: Clinical Trial Design
  • Figure 8.11: WT1 TCR: Clinical Trial Design
  • Figure 8.12: TBI-1301: Clinical Trial Design
  • Figure 9.1: TIL Cell Therapy: Geographical Distribution of Key Opinion Leaders
  • Figure 9.2: TIL Therapy: Prominent Key Opinion Leaders
  • Figure 9.3: TIL Cell Therapy: Manufacturing Process
  • Figure 9.4: LN-144: Clinical Trial Design
  • Figure 9.5: LN-145: Clinical Trial Design
  • Figure 9.6: Nantes University Hospital's TIL Therapy: Clinical Trial Design
  • Figure 9.7: Nantes University Hospital's TIL Therapy: Production Procedure
  • Figure 9.8: Netherlands Cancer Institute's TIL Therapy: Clinical Trial Design
  • Figure 10.1: Leukemia: Classification
  • Figure 10.2: Leukemia: Global Epidemiological Distribution
  • Figure 10.3: Lymphoma: Global Epidemiological Distribution
  • Figure 10.4: Multiple Myeloma: Global Epidemiological Distribution
  • Figure 10.5: Melanoma: Global Epidemiological Distribution
  • Figure 10.6: Lung Cancers: Classification
  • Figure 10.7: Lung Cancer: Global Epidemiological Distribution
  • Figure 10.8: Bladder Cancer: Global Epidemiological Distribution
  • Figure 10.9: Kidney Cancer: Global Epidemiological Distribution
  • Figure 10.10: Ovarian Cancer: Global Epidemiological Distribution
  • Figure 10.11: Breast Cancer: Global Epidemiological Distribution
  • Figure 11.1: Genome Editing Technologies: Applications
  • Figure 11.2: Genome Editing: Emerging Technology Platforms Used in T-Cell Platforms
  • Figure 11.3: T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
  • Figure 11.4: Properties of Enhanced T-Cell Platform
  • Figure 11.5: Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
  • Figure 12.1: T-Cell Immunotherapy Partnerships: Cumulative Trend (Pre-2011-2018)
  • Figure 12.2: T-Cell Immunotherapy Partnerships: Distribution by Type of Partnership Model, Pre-2011-2018
  • Figure 12.3: T-Cell Immunotherapy Partnerships: Most Active Players, Pre-2011 to 2018
  • Figure 12.4: T-Cell Immunotherapy Partnerships: Most Active Non-Industry Players, Pre- 2011-2018
  • Figure 12.5: T-Cell Immunotherapy Partnerships: Distribution by Type of Therapy, Pre- 2011-2018
  • Figure 12.6: T-Cell Immunotherapy Partnerships: Distribution by Product Therapy, Pre- 2011-2018
  • Figure 13.1: T-Cell Immunotherapies: Funding Instances, Cumulative Number of Investments by Year, Pre-2009-2017
  • Figure 13.2: T-Cell Immunotherapies: Funding Instances, Cumulative Distribution of Amount Invested by Year, Pre-2009-2017 (USD Million)
  • Figure 13.3: T-Cell Immunotherapies: Distribution by Type of Funding, Pre-2009-2017
  • Figure 13.4: T-Cell Immunotherapies: Total Amount Invested by Type of Funding, Pre-2009-2017 (USD Million)
  • Figure 13.5: T-Cell Immunotherapy: Most Active Players
  • Figure 14.1: Other T-Cell Immunotherapies: Distribution by Phase of Development
  • Figure 14.2: Other T-Cell Immunotherapies: Distribution by Target Therapeutic Area
  • Figure 14.3: Other T-Cell Immunotherapies: Distribution by Type of Cells
  • Figure 14.4: Other T-Cell Immunotherapies: Distribution by Source of T-Cells
  • Figure 14.5: Treg Cells: Functions
  • Figure 15.1: Cell Therapy Manufacturing: Key Steps
  • Figure 15.2: Cell Therapy Manufacturing: Scenarios
  • Figure 15.3: T-Cell Immunotherapy Manufacturing: Key Collaborations
  • Figure 16.1: Targeted Therapies: Pricing Model Based on Patient Segment
  • Figure 17.1: Overall T-Cell Immunotherapy Market, 2016-2026: Base Scenario (USD Billion)
  • Figure 17.2: T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2018, 2025 and 2030 (USD Billion)
  • Figure 17.3: T-Cell Immunotherapy Market: Distribution by Geography, 2018, 2025 and 2030 (USD Billion)
  • Figure 17.4: T-Cell Immunotherapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
  • Figure 17.5: Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
  • Figure 17.6: Kymriah (Novartis): Current Status of Development
  • Figure 17.7: Kymriah (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.8: Yescarta (Gilead Sciences): Current Status of Development
  • Figure 17.9: Yescarta (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.10: CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University): Current Status of Development
  • Figure 17.11: CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.12: GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
  • Figure 17.13: GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.14: TBI-1501 (Takara Bio / Jichi Medical University): Current Status of Development
  • Figure 17.15: TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.16: JCAR017 (Juno Therapeutics / Celgene): Current Status of Development
  • Figure 17.17: JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.18: MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center): Current Status of Development
  • Figure 17.19: MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.20: IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
  • Figure 17.21: IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.22: PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
  • Figure 17.23: PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.24: AUTO2 (Autolus): Current Status of Development
  • Figure 17.25: AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.26: AUTO3 (Autolus): Current Status of Development
  • Figure 17.27: AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.28: BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital): Current Status of Development
  • Figure 17.29: BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.30: CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital): Current Status of Development
  • Figure 17.31: CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.32: CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University): Current Status of Development
  • Figure 17.33: CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.34: LCAR-B38M CAR-T (Nanjing Legend Biotech): Current of Development
  • Figure 17.35: LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.36: CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
  • Figure 17.37: CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.38: bb2121 (Celgene / bluebird bio): Current Status of Development
  • Figure 17.39: bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.40: IMCgp100 (Immunocore): Current Status of Development
  • Figure 17.41: IMCgp100 (Immunocore) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.42: NY-ESO-1 TCR (Adaptimmune / GSK): Current Status of Development
  • Figure 17.43: NY-ESO-1 TCR (Adaptimmune / GSK) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.44: JTCR016 (Juno Therapeutics): Current Status of Development
  • Figure 17.45: JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.46: LTCR-H1-2 (Lion TCR / Agency for Science, Technology and Research / Third Affiliated Hospital / Sun Yat-Sen University): Current Status of Development
  • Figure 17.47: LTCR-H1-2 (Lion TCR / Agency for Science, Technology and Research / Third Affiliated Hospital / Sun Yat-Sen University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.48: ALT 801 (Altor Bioscience): Current Status of Development
  • Figure 17.49: ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.50: TBI-1301 (Takara Bio): Current Status of Development
  • Figure 17.51: TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.52: TIL (Nantes University Hospital): Current Status of Development
  • Figure 17.53: TIL (Nantes University Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.54: TIL (The Netherland Cancer Institute): Current Status of Development
  • Figure 17.55: TIL (The Netherland Cancer Institute) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.56: LN-144 (Iovance Biotherapeutics): Current Status of Development
  • Figure 17.57: LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.58: LN-145 (Iovance Biotherapeutics): Current Status of Development
  • Figure 17.59: LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 18.1: Promotional / Marketing Strategy: Product Website Analysis
  • Figure 18.2: Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
  • Figure 18.3: Product Website Analysis: Kymriah, Messages for Healthcare Professionals
  • Figure 18.4: Product Website Analysis: Kymriah, Messages for Patients
  • Figure 18.5: Product Website Analysis: Kymriah, Patient Support Program
  • Figure 18.6: Kymriah, Presence in Conferences
  • Figure 18.7: Product Website Analysis: Yescarta, Messages for Patients and Caregivers
  • Figure 18.8: Product Website Analysis: Kymriah, Kite Konnect
  • Figure 18.9: Product Website Analysis: Yescarta, Platform for Products Complaints, Reporting Adverse Events and Requesting Medical Information
  • Figure 18.10: Yescarta, Presence in Conferences
  • Figure 20.1: T-Cell Immunotherapy Market Landscape: Industry Participants
  • Figure 20.2: T-Cell Immunotherapy Market Landscape: Non-Industry Participants
  • Figure 20.3: T-Cell Immunotherapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Tables

  • Table 3.1: Different Types of Immunotherapies and their Mechanism of Action
  • Table 5.1: T-Cell Immunotherapies: Clinical Pipeline
  • Table 5.2: T-Cell Immunotherapies: Preclinical Pipeline
  • Table 6.1: CD19 CAR-T Immunotherapies: Competitive Landscape
  • Table 6.2: CD19 CAR-T Immunotherapies: Clinical Outcomes
  • Table 6.3: BCMA CAR-T Immunotherapies: Competitive Landscape
  • Table 6.4: BCMA CAR-T Immunotherapies: Clinical Outcomes
  • Table 6.5: Meso CAR-T Immunotherapies: Competitive Landscape
  • Table 6.6: Meso CAR-T Immunotherapies: Clinical Outcomes
  • Table 6.7: GD2 CAR-T Immunotherapies: Competitive Landscape
  • Table 6.8: GD2 CAR-T Immunotherapies: Clinical Outcomes
  • Table 6.9: T-Cell Immunotherapies: Clinical Trials
  • Table 7.1: Key Characteristics of CAR-T Cells
  • Table 7.2: CAR-T Therapies: Information on Constructs of Clinical Candidates
  • Table 7.3: Comparison Between First and Second Generation CAR-Ts
  • Table 7.4: Grading Criteria for Cytokine Release Syndrome
  • Table 7.5: Safety Switches under Development for CAR-T Therapies
  • Table 7.6: CD19 CAR-T Immunotherapies: Preclinical Results
  • Table 7.7: Other Targets under Clinical / Preclinical Studies for CAR-T Therapies
  • Table 7.8: Kymriah®: Clinical Studies
  • Table 7.9: Kymriah®: Clinical Trial Endpoints (Acute Lymphoblastic Leukemia)
  • Table 7.10: Kymriah®: Clinical Trial Endpoints (Chronic Lymphocytic Leukemia / Multiple Myeloma / Non-Hodgkin Lymphoma)
  • Table 7.11: JCAR Series: Molecules in Clinical Development
  • Table 7.12: JCAR Series: CAR-T Design
  • Table 7.13: JCAR014: Current Status of Development
  • Table 7.14: JCAR017: Current Status of Development
  • Table 7.15: JCAR018: Current Status of Development
  • Table 7.16: JCAR020: Current Status of Development
  • Table 7.17: JCAR023: Current Status of Development
  • Table 7.18: JCAR024: Current Status of Development
  • Table 7.19: JCAR Series: Clinical Trial Endpoints (Phase II)
  • Table 7.20: JCAR Series: Clinical Trial Endpoints (Phase I)
  • Table 7.21: JCAR Series: Dosage Regimen
  • Table 7.22: Yescarta®: Clinical Studies
  • Table 7.23: Yescarta®: Clinical Trial Endpoints
  • Table 7.24: Yescarta®: Results of ZUMA-1 Phase II (6 months Follow-Up)
  • Table 7.25: Yescarta®: Results of ZUMA-1 Phase II Results (≥3 months Follow-Up)
  • Table 7.26: Yescarta®: Results of ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
  • Table 7.27: CBM CAR-T Series: Clinical Products
  • Table 7.28: CBM-CD19.1 CAR-T: Clinical Studies
  • Table 7.29: CBM-CD20 CAR-T: Current Status of Development
  • Table 7.30: CBM-CD30.1 CAR-T: Current Status of Development
  • Table 7.31: CBM-EGFR.1 CAR-T: Current Status of Development
  • Table 7.32: CBM CAR-T Series: Clinical Trial Endpoints
  • Table 7.33: CBM CAR-T Series: Patent Portfolio
  • Table 7.34: Takara Bio's CD19 CAR-T: Current Status of Development
  • Table 7.35: Takara Bio's CD19 CAR-T: Clinical Trial Endpoints
  • Table 7.36: TBI-1501: Dosage Regimen
  • Table 7.37: AUTO2: Clinical Studies
  • Table 7.38: AUTO3: Clinical Studies
  • Table 7.39: Autolus' Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 7.40: Sinobioway Cell Therapy's CD19 CAR-T Therapy: Clinical Studies
  • Table 7.41: Sinobioway Cell Therapy's EPCAM CAR-T Therapy: Clinical Studies
  • Table 7.42: Sinobioway Cell Therapy' Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 7.43: Phase I/II or Phase II CAR-T Therapies of Industry Players
  • Table 8.1: CAR-T Cell and TCR Based Therapies: Key Differences
  • Table 8.2: TCR Therapies: Principle Investigators
  • Table 8.3: NY-ESO TCR: Clinical Studies
  • Table 8.4: MAGE-A10: Clinical Studies
  • Table 8.5: MAGE A-4: Current Status of Development
  • Table 8.6: AFP T-Cell: Current Status of Development
  • Table 8.7: NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
  • Table 8.8: MAGE A-10 / MAGE A-4 / AFP TCR: Clinical Trial Endpoints
  • Table 8.9: ALT-801: Clinical Studies
  • Table 8.10: ALT-801: Clinical Trial Endpoints
  • Table 8.11: IMCgp100: Clinical Studies
  • Table 8.12: IMCgp100: Clinical Trial Endpoints
  • Table 8.13: JTCR016: Clinical Studies
  • Table 8.14: JTCR016: Clinical Trial Endpoints
  • Table 8.15: WT1 TCR: Clinical Studies
  • Table 8.16: WT1 TCR: Clinical Trial Endpoints
  • Table 8.17: TBI-1301: Clinical Studies
  • Table 8.18: TBI-1301: Clinical Trial Endpoints
  • Table 9.1: TIL Therapies: Principle Investigators
  • Table 9.2: LN-144: Current Status of Development
  • Table 9.3: LN-144: Clinical Trial Endpoints
  • Table 9.4: LN-145: Current Status of Development
  • Table 9.5: LN-145: Clinical Trial Endpoints
  • Table 9.6: LN-144: Patent Portfolio
  • Table 9.7: Nantes University Hospital's TIL Therapy: Clinical Trial Endpoints
  • Table 9.8: Netherlands Cancer Institute's TIL Therapy: Clinical Trial Endpoints
  • Table 10.1: Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 10.2: Leukemia: List of Marketed Targeted Therapeutics
  • Table 10.3: Lymphoma: List of Marketed Targeted Therapeutics
  • Table 10.4: T-Cell Immunotherapies: Targets under Investigation for Leukemia
  • Table 10.5: T-Cell Immunotherapies: Targets under Investigation for Lymphoma
  • Table 10.6: Multiple Myeloma: List of Marketed Targeted Therapeutics
  • Table 10.7: T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
  • Table 10.8: Melanoma: List of Marketed Targeted Therapeutics
  • Table 10.9: TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
  • Table 10.10: Lung Cancer: List of Marketed Targeted Therapeutics
  • Table 10.11: T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
  • Table 10.12: Bladder Cancer: List of Marketed Targeted Therapeutics
  • Table 10.13: Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
  • Table 10.14: Ovarian Cancer: List of Marketed Targeted Therapeutics
  • Table 10.15: T-Cell Immunotherapy: Targets under Investigation for Ovarian Cancer
  • Table 10.16: Breast Cancer: List of Marketed Targeted Therapeutics
  • Table 10.17: T-Cell Immunotherapies: Targets under Investigation for Breast Cancer
  • Table 11.1: Editas Medicine: CRISPR / Cas9 Technology, Research Publications
  • Table 11.2: Editas Medicine: Funding Instances
  • Table 11.3: Editas Medicine: Collaborations
  • Table 11.4: Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
  • Table 11.5: Intellia Therapeutics: Funding Instances
  • Table 11.6: Intellia Therapeutics: Collaborations
  • Table 11.7: CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
  • Table 11.8: CRISPR Therapeutics: Funding Instances
  • Table 11.9: CRISPR Therapeutics: Collaborations
  • Table 11.10: Cellectis: Funding Instances
  • Table 11.11: Cellectis: Collaborations
  • Table 11.12: bluebird bio: megaTAL Technology, Research Publications
  • Table 11.13: bluebird bio: Funding Instances
  • Table 11.14: bluebird bio: Collaborations
  • Table 11.15: Sangamo BioSciences: Funding Instances
  • Table 11.16: Sangamo BioSciences: Collaborations
  • Table 11.17: Unum Therapeutics: Funding Instances
  • Table 11.18: Unum Therapeutics: NKR-T Platform Related Collaborations
  • Table 11.19: Celyad: Funding Instances
  • Table 11.20: Celyad: Collaborations
  • Table 11.21: Intrexon: Funding Instances
  • Table 11.22: Intrexon: Collaborations
  • Table 11.23: Bellicum Pharmaceuticals: Key Switch Technologies
  • Table 11.24: Bellicum Pharmaceuticals: Switch Technologies, Research Publications
  • Table 11.25: Bellicum Pharmaceuticals: Funding Instances
  • Table 11.26: Bellicum Pharmaceuticals: Collaborations
  • Table 11.27: Theravectys: Funding Instances
  • Table 11.28: Technologies For CAR-T Safety Enhancement
  • Table 11.29: Formula Pharmaceuticals: Collaborations
  • Table 11.30: Celyad: Allogenic Platform Related Collaborations
  • Table 12.1: T-Cell Immunotherapy Market: Partnerships
  • Table 13.1: T-Cell Immunotherapy Market: Funding and Investments, Pre-2009-2017
  • Table 13.2: T-Cell Immunotherapy: Summary of Investments
  • Table 14.1: List of Other Novel T-Cell Immunotherapies
  • Table 14.2: Treg Cells: Properties
  • Table 15.1: Cell Therapy Manufacturing: Companies with In-house Capabilities
  • Table 15.2: Cell Therapy Manufacturing: Contract Manufacturers
  • Table 16.1: Price of Marketed Gene / Cell Therapies
  • Table 16.2: Price of Marketed Targeted Drugs
  • Table 16.3: T-Cell Immunotherapies: Expert Opinions on Pricing
  • Table 16.4: CAR-T Therapies: Reimbursement Landscape
  • Table 17.1: T-Cell Immunotherapies: List of Forecasted Molecules
  • Table 18.1: Kymriah®: Drug Overview
  • Table 18.2: Yescarta®: Drug Overview
  • Table 19.1: Adaptimmune Therapeutics: Company Profile
  • Table 19.2: Autolus: Company Profile
  • Table 19.3: bluebird bio: Company Profile
  • Table 19.4: CARsgen Therapeutics: Company Profile
  • Table 19.5: Celgene: Company Profile
  • Table 19.6: Cell Medica: Company Profile
  • Table 19.7: Cellectis: Company Profile
  • Table 19.8: Cellular Biomedicine Group: Company Profile
  • Table 19.9: Immunocore: Company Profile
  • Table 19.10: Innovative Cellular Therapeutics: Company Profile
  • Table 19.11: Iovance Biotherapeutics: Company Profile
  • Table 19.12: Kite Pharma: Company Profile
  • Table 19.13: Lion TCR: Company Profile
  • Table 19.14: Novartis: Company Profile
  • Table 19.15: Sinobioway Cell Therapy: Company Profile
  • Table 19.16: Takara Bio: Company Profile
  • Table 19.17: Unum Therapeutics: Company Profile
  • Table 19.18: ZIOPHARM Oncology: Company Profile
  • Table 21.1: Cell Therapies: Key Highlights
  • Table 21.2: Celyad: Key Highlights
  • Table 21.3: Changhai Hospital: Key Highlights
  • Table 21.4: Iovance Biotherapeutics: Key Highlights
  • Table 21.5: Kite Pharma: Key Highlights
  • Table 21.6: Lion TCR: Key Highlights
  • Table 21.7: Theravectys: Key Highlights
  • Table 21.8: TxCell: Key Highlights
  • Table 21.9: University of Colorado: Key Highlights
  • Table 21.10: Waisman Biomanufacturing: Key Highlights
  • Table 22.1: T-Cell Immunotherapy Pipeline: Distribution by Type of Product
  • Table 22.2: T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
  • Table 22.3: T-Cell Immunotherapy Pipeline: Distribution by Type of Developer and Type of Product
  • Table 22.4: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
  • Table 22.5: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development and Type of Product
  • Table 22.6: T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Areas
  • Table 22.7: T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Areas and Type of Product
  • Table 22.8: T-Cell Immunotherapy Pipeline: Popular Target Indications
  • Table 22.9: CAR-T Immunotherapy Pipeline: Popular Target Indications
  • Table 22.10: TCR Immunotherapy Pipeline: Popular Target Indications
  • Table 22.11: TIL Immunotherapy Pipeline: Popular Target Indications
  • Table 22.12: CAR-T Cell Immunotherapy Pipeline: Distribution by Target Antigen
  • Table 22.13: TCR Cell Immunotherapy Pipeline: Distribution by Target Antigen
  • Table 22.14: T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells
  • Table 22.15: T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells and Type of Product
  • Table 22.16: T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
  • Table 22.17: T-Cell Immunotherapy Pipeline: Distribution by Route of Administration
  • Table 22.18: T-Cell Immunotherapy Pipeline: Distribution by Route of Administration and Type of Product
  • Table 22.19: T-Cell Immunotherapy Clinical Pipeline: Active Industry Players
  • Table 22.20: T-Cell Immunotherapy Preclinical Pipeline: Active Industry Players
  • Table 22.21: T-Cell Immunotherapy Clinical Pipeline: Active Non-Industry Players
  • Table 22.22: T-Cell Immunotherapy Preclinical Pipeline: Active Non-Industry Players
  • Table 22.23: T-Cell Immunotherapies: Popular Targets in Hematological Cancer
  • Table 22.24: T-Cell Immunotherapies: Popular Targets in Solid Tumor
  • Table 22.25: CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
  • Table 22.26: CAR-T Clinical Trials: Geographical Landscape (Pre-2016 and 2018)
  • Table 22.27: T-Cell Immunotherapies, Clinical Trials: Distribution by Type of Product
  • Table 22.28: T-Cell Immunotherapies, Clinical Trials: Distribution by Phase of Development
  • Table 22.29: T-Cell Immunotherapies, Clinical Trials: Distribution by Phase of Development and Type of Product
  • Table 22.30: T-Cell Immunotherapies, Clinical Trials: Distribution by Patient Segment
  • Table 22.31: T-Cell Immunotherapies, Clinical Trials: Distribution by Patient Segment and Type of Product
  • Table 22.32: T-Cell Immunotherapies, Clinical Trials: Distribution by Type of Therapy
  • Table 22.33: T-Cell Immunotherapies, Clinical Trials: Distribution by Type of Therapy and Type of Product
  • Table 22.34: CAR-Constructs: Distribution by Generation of CAR-T Therapies
  • Table 22.35: CAR-Constructs: Distribution by Type of scFv used
  • Table 22.36: CAR-Constructs: Distribution by Type of Vector
  • Table 22.37: CAR-Constructs: Distribution by Type of Co-Stimulatory Domain(s)
  • Table 22.38: T-Cell Immunotherapy Partnerships: Cumulative Trend, Pre-2011-2018
  • Table 22.39: T-Cell Immunotherapy Partnerships: Distribution by Type of Partnership Model, Pre-2018-2018
  • Table 22.40: T-Cell Immunotherapy Partnerships: Most Active Players
  • Table 22.41: T-Cell Immunotherapy Partnerships: Most Active Non-Industry Players
  • Table 22.44: T-Cell Immunotherapy Partnerships: Distribution by Type of Therapy
  • Table 22.45: T-Cell Immunotherapy Partnerships: Distribution by Product Therapy
  • Table 22.46: T-Cell Immunotherapy Funding Instances: Cumulative Number of Investments by Year, Pre-2009-2017
  • Table 22.47: T-Cell Immunotherapy Funding Instances: Cumulative Amount Invested by Year, Pre-2009-2017 (USD Million)
  • Table 22.48: T-Cell Immunotherapies Funding Instances: Distribution by Type of Funding
  • Table 22.49: T-Cell Immunotherapies Funding Instances: Distribution by Total Amount Invested by Type of Funding (USD Million)
  • Table 22.50: T-Cell Immunotherapies: Analysis of Most Active Industry Players by Number of Funding Instances
  • Table 22.51: Other T-Cell Immunotherapies: Distribution by Phase of Development
  • Table 22.52: Other T-Cell Immunotherapies: Distribution by Target Therapeutic Areas
  • Table 22.53: Other T-Cell Immunotherapies: Distribution by Type of Cells
  • Table 22.54: Other T-Cell Immunotherapies: Distribution by Source of T-Cells
  • Table 22.55: Overall T-Cell Immunotherapy Market, 2018-2030: Conservative Scenario (USD Billion)
  • Table 22.56: Overall T-Cell Immunotherapy Market, 2018-2030: Base Scenario (USD Billion)
  • Table 22.57: Overall T-Cell Immunotherapy Market, 2018-2030: Opportunistic Scenario (USD Billion)
  • Table 22.58: T-Cell Immunotherapy Market: Distribution by Type of Product, 2018, 2025 and 2030 (USD Billion)
  • Table 22.59: T-Cell Immunotherapy Market: Distribution by Geography, 2018, 2025 and 2030 (USD Billion)
  • Table 22.60: T-Cell Immunotherapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
  • Table 22.61: Overall CAR-T Therapy Market, 2018-2030: Conservative Scenario (USD Billion)
  • Table 22.62: Overall CAR-T Therapy Market, 2018-2030: Base Scenario (USD Billion)
  • Table 22.63: Overall CAR-T Therapy Market, 2018-2030: Opportunistic Scenario (USD Billion)
  • Table 22.64: Kymriah® (Novartis) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.65: Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.66: Kymriah® (Novartis) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.67: Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.68: Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.69: Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.70: CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.71: CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.72: CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.73: GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.74: GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.75: GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.76: TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.77: TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.78: TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.79: JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.80: JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.81: JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.82: MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.83: MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.84: MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.85: IM19 CAR-T (Beijing Immunochina Medical Science and Technology) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.86: IM19 CAR-T (Beijing Immunochina Medical Science and Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.87: IM19 CAR-T (Beijing Immunochina Medical Science and Technology) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.88: PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.89: PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.90: PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.91: AUTO2 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.92: AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.93: AUTO2 (Autolus) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.94: AUTO3 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.95: AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.96: AUTO3 (Autolus) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.97: BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.98: BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.99: BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.100: CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.101: CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.102: CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.103: CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.104: CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.105: CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.106: LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.107: LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.108: LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.109: CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.110: CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.111: CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.112: bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.113: bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.114: bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.115: IMCgp100 (Immunocore) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.116: IMCgp100 (Immunocore) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.117: IMCgp100 (Immunocore) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.118: NY-ESO-1 TCR (Adaptimmune / GSK) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.119: NY-ESO-1 TCR (Adaptimmune / GSK) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.120: NY-ESO-1 TCR (Adaptimmune / GSK) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.121: JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.122: JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.123: JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.124: LTCR-H1-2 (Lion TCR / Agency for Science, Technology and Research / Third Affiliated Hospital / Sun Yat-Sen University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.125: LTCR-H1-2 (Lion TCR / Agency for Science, Technology and Research / Third Affiliated Hospital / Sun Yat-Sen University) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.126: LTCR-H1-2 (Lion TCR / Agency for Science, Technology and Research / Third Affiliated Hospital / Sun Yat-Sen University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.127: ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.128: ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.129: ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.130: TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.131: TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.132: TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.133: TIL (Nantes University Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.134: TIL (Nantes University Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.135: TIL (Nantes University Hospital) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.136: TIL (Netherlands Cancer Institute) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.137: TIL (Netherlands Cancer Institute) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.138: TIL (Netherlands Cancer Institute) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.139: LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.140: LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.141: LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
  • Table 22.142: LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 22.143: LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 22.144: LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. A*STAR's Genome Institute of Singapore
  • 2. Abramson Cancer Center
  • 3. AbVitro
  • 4. Acerta Pharma
  • 5. Acer Therapeutics
  • 6. Adaptimmune Therapeutics
  • 7. Adicet Bio
  • 8. Adimab
  • 9. Advanced BioScience Laboratories
  • 10. Advent Bioservices
  • 11. Adverum Biotechnologies
  • 12. Aeon Therapeutics (Shanghai)
  • 13. AFG Private Equity
  • 14. Affiliated Hospital to Academy of Military Medical Sciences
  • 15. AgenTus Therapeutics
  • 16. Agreen Biotech
  • 17. AGF Private Equity
  • 18. AJU IB Investment
  • 19. Aokai Biotech
  • 20. Akron Biotech
  • 21. Alaska Permanent Fund
  • 22. Albert Einstein College of Medicine
  • 23. Alexandria Venture Investments
  • 24. Allergan
  • 25. Alta Partners
  • 26. Alpine Immune Sciences
  • 27. Altor BioScience
  • 28. Amsterdam BioTherapeutics Unit
  • 29. Amgen
  • 30. Anhui Kedgene Biotechnology
  • 31. Anhui Provincial Hospital
  • 32. Antagene
  • 33. Anterogen
  • 34. apceth Biopharma
  • 35. Aquilo Capital Management
  • 36. ARBELE
  • 37. ARCH Venture Partners
  • 38. Argos Therapeutics
  • 39. ARIAD Pharmaceuticals
  • 40. Arix Bioscience
  • 41. Astellas Pharma
  • 42. AstraZeneca
  • 43. Asymptote
  • 44. Atara Biotherapeutics
  • 45. AT Impf
  • 46. Atlantic Bio GMP
  • 47. Atlas Venture
  • 48. Atreca
  • 49. Aurora Biopharma
  • 50. Autolus
  • 51. Avacta
  • 52. AVG Ventures
  • 53. BankInvest Biomedical Venture
  • 54. Batavia Biosciences
  • 55. Bavarian Nordic
  • 56. Baxalta
  • 57. Bayer
  • 58. Baylor College of Medicine
  • 59. Beijing Biohealthcare Biotechnology
  • 60. Beijing Doing Biomedical
  • 61. Beijing Genomics Institute
  • 62. Beijing Immunochina Medical Science and Technology
  • 63. Beijing Sanwater Biological Technology
  • 64. Beijing You'an Hospital
  • 65. Bellicum Pharmaceuticals
  • 66. Beth Israel Deaconess Medical Center
  • 67. Bezos Expeditions
  • 68. Bill & Melinda Gates Foundation
  • 69. BioAtla
  • 70. Bio Elpida
  • 71. Biogen
  • 72. BioLife Solutions
  • 73. Biomedical Catalyst
  • 74. BioNTech Innovative Manufacturing Services
  • 75. bluebird bio
  • 76. Boehringer Ingelheim
  • 77. Brace Pharma Capital
  • 78. Brammer Bio
  • 79. Broadfin Capital
  • 80. Broad Institute
  • 81. Bristol-Myers Squibb
  • 82. Cabaret Biotech
  • 83. Caladrius Biosciences
  • 84. California Institute for Regenerative Medicine
  • 85. Cancer Research UK
  • 86. Cancer Prevention Research Institute of Texas
  • 87. Captain T Cell
  • 88. Cardiff University
  • 89. Cartherics
  • 90. Caribou Biosciences
  • 91. Carina Biotech
  • 92. CARsgen Therapeutics
  • 93. Casdin Capital
  • 94. Casebia Therapeutics
  • 95. Cell Biotech
  • 96. Celdara Medical
  • 97. Cellectis
  • 98. Cell Design Labs
  • 99. Celgene
  • 100. Cell and Gene Therapy Catapult
  • 101. Cellenkos
  • 102. Cell Medica
  • 103. Cellular Biomedicine Group
  • 104. CELLforCURE
  • 105. Cell Therapies
  • 106. Cellular Therapeutics
  • 107. Celyad
  • 108. Center for Cell and Gene Therapy
  • 109. Center for Cell Manufacturing Ireland, NUI Galway
  • 110. Center for Research in Transplantation and Immunology
  • 111. Changhai Hospital
  • 112. CHDI Foundation
  • 113. Chengdu MedGenCell
  • 114. Chiesi Farmaceutici
  • 115. Children's Hospital of Philadelphia
  • 116. Children's Mercy Hospital
  • 117. Children's Oncology Group
  • 118. Children's Research Institute
  • 119. Chinese Academy of Sciences
  • 120. Chinese PLA General Hospital
  • 121. Christie NHS Foundation Trust
  • 122. Clough Capital Partners
  • 123. City of Hope National Medical Center
  • 124. Cognate BioServices
  • 125. Columbia University
  • 126. Cook MyoSite
  • 127. Copenhagen University Hospital
  • 128. Cormorant Asset Management
  • 129. Cowen Private Investments
  • 130. CRISPR Therapeutics
  • 131. Cryoport
  • 132. CureVac
  • 133. Cystic Fibrosis Foundation Therapeutics
  • 134. CytoLumina Technologies
  • 135. Cytovance Biologics
  • 136. Daiichi Sankyo
  • 137. Dana-Farber Cancer Institute
  • 138. Dangdai International Group
  • 139. Dartmouth College
  • 140. Deerfield Management
  • 141. Delenex Therapeutics
  • 142. Dendreon
  • 143. dievini Hopp Biotech
  • 144. Dongguan People's Hospital
  • 145. Dow AgroSciences
  • 146. DS Asset Management
  • 147. Duke Cancer Institute
  • 148. Easton Capital Investment Group
  • 149. EcoR1 Capital
  • 150. Editas Medicine
  • 151. Eli Lilly
  • 152. Edmond de Rothschild Investment Partners
  • 153. Endocyte
  • 154. ERS Genomics
  • 155. Eutilex
  • 156. Eureka Therapeutics
  • 157. F1 BioVentures
  • 158. F1 Oncology
  • 159. F2 Ventures
  • 160. Fate Therapeutics
  • 161. FetoLumina Technologies
  • 162. FGP Capital
  • 163. Financière IDAT
  • 164. Finnish Funding Agency for Technology and Innovation
  • 165. First Affiliated Hospital of Chengdu Medical College
  • 166. First Affiliated Hospital of Harbin Medical University
  • 167. First Affiliated Hospital of Sun Yat-sen University
  • 168. First Affiliated Hospital of Wenzhou Medical University
  • 169. First Affiliated Hospital of Zhejiang University
  • 170. First People's Hospital of Foshan
  • 171. F-Prime Capital
  • 172. Five Prime Therapeutics
  • 173. Flagship Pioneering
  • 174. Forbion Capital Partners
  • 175. Fondazione Telethon and Ospedale San Raffaele
  • 176. Foresite Capital
  • 177. Forevertek Biotechnology
  • 178. Formula Pharmaceuticals
  • 179. Fosun Pharmaceutical
  • 180. Fortress Biotech
  • 181. Franklin Templeton Investments
  • 182. Fred Hutchinson Cancer Research Center
  • 183. Fraunhofer Institute for Cell Therapy and Immunology
  • 184. Friedreich's Ataxia Research Alliance
  • 185. Fuda Cancer Hospital
  • 186. Fudan University
  • 187. Fujian Medical University
  • 188. GammaCell Bio-Technologies
  • 189. GammaDelta Therapeutics
  • 190. Gadeta
  • 191. Gene and Cell Therapy Lab
  • 192. GE Healthcare Life Sciences
  • 193. Ghent University Hospital
  • 194. GigaGen
  • 195. Gilead Sciences
  • 196. GlaxoSmithKline
  • 197. G.N. Tech Venture Capital
  • 198. Google Ventures
  • 199. Green Cross Cell
  • 200. Guangzhou Eighth People's Hospital
  • 201. Guangzhou First People's Hospital
  • 202. Guangzhou Xiangxue Pharmaceutical
  • 203. Guangzhou YiYang Biological Technology
  • 204. Guangdong Zhaotai InVivo Biomedicine
  • 205. Guy's and St Thomas' NHS Foundation Trust
  • 206. Hadassah Medical Center
  • 207. Hangzhou Cancer Hospital
  • 208. Harbin Medical University
  • 209. Harvard University
  • 210. Hebei Senlang Biotechnology
  • 211. Henan Cancer Hospital
  • 212. HengRui YuanZheng Bio-Technology
  • 213. Herlev Hospital
  • 214. Hitachi Chemical Advanced Therapeutics Solutions
  • 215. H. Lee Moffitt Cancer Center and Research Institute
  • 216. Howard Hughes Medical Institute
  • 217. Human Stem Cells Institute
  • 218. Hunan Zhaotai Yongren Medical Innovation
  • 219. iCarTAB BioMed
  • 220. iCell Gene Therapeutics
  • 221. Immatics Biotechnologies
  • 222. Immunocore
  • 223. Immune Therapeutics
  • 224. Immunovative Therapies
  • 225. Imperial College London
  • 226. Imperial Innovations Group
  • 227. Innovate UK
  • 228. Innovative Cellular Therapeutics
  • 229. Innovative Genomins Institute
  • 230. Intellia Therapeutics
  • 231. Intrexon
  • 232. Institut Curie
  • 233. Institut Pasteur
  • 234. Boston Children's Hospital
  • 235. Instituto de Salud Carlos III
  • 236. Invesco Perpetual
  • 237. Iovance Biotherapeutics
  • 238. Iowa State University Research Foundation
  • 239. Janus Capital Management
  • 240. Janssen Biotech
  • 241. Japan Science and Technology Agency
  • 242. Jazz Pharmaceuticals
  • 243. JCR Pharmaceuticals
  • 244. Jennison Associates
  • 245. Jiangsu Cancer Hospital
  • 246. JIC GenesisFountain Healthcare Ventures
  • 247. John Goldman Centre for Cellular Therapy
  • 248. Johns Hopkins University
  • 249. Jolly Innovation Ventures
  • 250. Jonsson Comprehensive Cancer Center
  • 251. Juno Therapeutics
  • 252. JW Biotechnology
  • 253. Kaitai Capital
  • 254. Karolinska University Hospital
  • 255. KBI Biopharma
  • 256. Keio University
  • 257. Khosla Ventures
  • 258. King's College London
  • 259. Kite Pharma
  • 260. Kolon Investment
  • 261. KTB Ventures
  • 262. Legend Capital
  • 263. Leiden University Medical Center
  • 264. Leucid Bio
  • 265. Lexicon Pharmaceuticals
  • 266. Life Technologies
  • 267. Lifeline Ventures
  • 268. Lilly Asia Ventures
  • 269. Lion TCR
  • 270. Living Pharmaceticals
  • 271. Lonza
  • 272. Loyola University
  • 273. Lübeck Institute of Experimental Dermatology
  • 274. MabQuest
  • 275. Malin
  • 276. Marino Biotechnology
  • 277. MaSTherCell
  • 278. Massachusetts General Hospital Cancer Center
  • 279. Matrix Capital Management
  • 280. MaxCyte
  • 281. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • 282. MD Anderson Cancer Center
  • 283. Medarex
  • 284. Medical College of Wisconsin
  • 285. Medicxi Ventures
  • 286. Medigene
  • 287. MEDINET
  • 288. MedImmune
  • 289. Medpost Urgent Care
  • 290. Memorial Sloan Kettering Cancer Center
  • 291. Merck
  • 292. Merck Serono
  • 293. Merlin Nexus
  • 294. Mie University
  • 295. Millennium Pharmaceuticals
  • 296. Miltenyi Biotec
  • 297. MingJu Therapeutics (Shanghai)
  • 298. Molecular and Cellular Therapeutics
  • 299. MolMed
  • 300. MPM Capital
  • 301. Mustang Bio
  • 302. Nanjing Children's Hospital
  • 303. Nanjing Legend Biotech
  • 304. Nantes University Hospital
  • 305. NantKwest
  • 306. National Cancer Institute
  • 307. National Heart, Lung, and Blood Institute
  • 308. National Institute of Allergy and Infectious Diseases
  • 309. National Institutes of Health
  • 310. National University of Singapore
  • 311. Navy General Hospital (Beijing)
  • 312. NCL Innovation
  • 313. Nextech Invest
  • 314. New Enterprise Associates
  • 315. New Leaf Venture Partners
  • 316. New River Management
  • 317. NewVa Capital Partners
  • 318. New York Medical College
  • 319. Ningbo Cancer Hospital
  • 320. Nikon CeLL innovation
  • 321. Nipro
  • 322. Noile-Immune Biotech
  • 323. Novartis
  • 324. Novo Ventures
  • 325. Oaktree Capital Management
  • 326. ODYSSEE Venture
  • 327. Omega Funds
  • 328. Oncodesign
  • 329. OncoTracker
  • 330. OnCyte
  • 331. Ono Pharmaceutical
  • 332. Onyx Pharmaceuticals
  • 333. Opexa Therapeutics
  • 334. Opus Bio
  • 335. OrbiMed HealthCare Fund Management
  • 336. Ospedale Pediatrico Bambino Gesù
  • 337. Oxford BioMedica
  • 338. Oxford MEStar
  • 339. Partners Innovation Fund
  • 340. Peking University
  • 341. Perceptive Advisors
  • 342. Peter MacCallum Cancer Centre
  • 343. Perceptive Advisors
  • 344. PersonGen BioTherapeutics (Suzhou)
  • 345. Pfizer
  • 346. PharmaCell
  • 347. Pharmicell
  • 348. Pinze Lifetechnology
  • 349. Polaris Partners
  • 350. PolyBioCept
  • 351. Pontifax
  • 352. Poseida Therapeutics
  • 353. Praxis Pharmaceutical
  • 354. Precision BioSciences
  • 355. Precision Genome Engineering
  • 356. Princess Margaret Cancer Centre
  • 357. Progenitor Cell Therapy
  • 358. ProMab Biotechnologies
  • 359. Puma Biotechnology
  • 360. Quogue Capital
  • 361. RA Capital Management
  • 362. Ramius Capital Group
  • 363. Rayne Cell Therapy Suite
  • 364. RedoxTherapeis
  • 365. Redmile Group
  • 366. Relieve Genetics
  • 367. Regeneron Pharmaceuticals
  • 368. Remeditex Ventures
  • 369. Renji Hospital
  • 370. Renmin Hospital of Wuhan University
  • 371. Ridgeback Capital Management
  • 372. Roche
  • 373. Rockland Immunochemicals
  • 374. Roger Williams Medical Center
  • 375. RoslinCT
  • 376. Royal Adelaide Hospital Cancer Centre
  • 377. Roswell Park Comprehensive Cancer Center
  • 378. RXi Pharmaceuticals
  • 379. Sabby Management
  • 380. Sangamo Therapeutics
  • 381. Sanofi-Genzyme BioVentures
  • 382. San Raffaele Hospital
  • 383. Scottish National Blood Transfusion Service
  • 384. Scottish Investment Bank
  • 385. Seattle Genetics
  • 386. Seattle Children's Hospital
  • 387. Second Affiliated Hospital of Guangzhou Medical University
  • 388. Sectoral Asset Management
  • 389. Second Military Medical University
  • 390. Second Xiangya Hospital of Central South University
  • 391. Servier
  • 392. Shanghai Bioray Laboratory
  • 393. Shanghai Changzheng Hospital
  • 394. Shanghai Cell Therapy Engineering Technology Research Center
  • 395. Shanghai Chest Hospital
  • 396. Shanghai Children's Medical Center
  • 397. Shanghai GeneChem
  • 398. Shanghai General Hospital
  • 399. Shanghai Houchao Biotechnology
  • 400. Shanghai Jiao Tong University School of Medicine
  • 401. Shanghai Longyao Biotechnology
  • 402. Shanghai Sunway Biotech
  • 403. Shanghai Tongji Hospital
  • 404. Shanghai Unicar-Therapy Bio-medicine Technology
  • 405. Sheba Medical Center
  • 406. ShengJing360.com
  • 407. Shenzhen BinDeBio
  • 408. Shenzhen Geno-immune Medical Institute
  • 409. Shenzhen Hornetcorn Biotechnology
  • 410. Shenzhen Institute for Innovation and Translational Medicine
  • 411. Shenzhen Second People's Hospital
  • 412. Shenzhen Sibiono GeneTech
  • 413. Shire International
  • 414. Sidney Kimmel Comprehensive Cancer Center
  • 415. Sigma-Aldrich
  • 416. Shionogi
  • 417. Sichuan University
  • 418. Sinobioway Cell Therapy
  • 419. Sinobioway Group
  • 420. SNU Bio Angel
  • 421. Southwest General Health Center
  • 422. Sorrento Therapeutics
  • 423. Spark Therapeutics
  • 424. Square 1 Bank
  • 425. Stage Cell Therapeutics
  • 426. Stanford University
  • 427. St. George's Hospital
  • 428. St. Jude Children's Research Hospital
  • 429. SOTIO
  • 430. StrideBio
  • 431. SR One
  • 432. SunTerra Capital
  • 433. Sun Yat-sen University
  • 434. Syncona
  • 435. SyndicateRoom
  • 436. Tactiva Therapeutics
  • 437. Takeda Pharmaceutical
  • 438. Takara Bio
  • 439. Targazyme
  • 440. Target ALS Foundation
  • 441. TC BioPharm
  • 442. T-Cell Factory
  • 443. TCR2 Therapeutics
  • 444. Tel Aviv Sourasky Medical Center
  • 445. TeneoBio
  • 446. Tesaro
  • 447. Tessa Therapeutics
  • 448. Tethys Health Ventures
  • 449. Terumo Medical
  • 450. Nanjing Drum Tower Hospital
  • 451. Beijing Pregene Science and Technology Company
  • 452. The First Affiliated Hospital of Guangdong Pharmaceutical University
  • 453. The First Affiliated Hospital of Guangzhou Medical University
  • 454. The First Affiliated Hospital of Soochow University
  • 455. The First People's Hospital of Yunnan
  • 456. The First People's Hospital of Lianyungang
  • 457. Thiel Capital
  • 458. Netherlands Cancer Institute
  • 459. The Ohio State University Comprehensive Cancer Center
  • 460. The Pregene (ShenZhen) Biotechnology Company
  • 461. Theravectys
  • 462. Henan University of Traditional Chinese Medicine
  • 463. Texas Emerging Technology Fund
  • 464. Thermo Fisher Scientific
  • 465. The Wistar Institute
  • 466. Third Military Medical University
  • 467. Third Rock Ventures
  • 468. Third Security
  • 469. Three Arch Opportunity Fund
  • 470. TILT Biotherapeutics
  • 471. Tianjin Medical University Cancer Institute and Hospital
  • 472. TiGenix
  • 473. TissueGene-C
  • 474. Tmunity Therapeutics
  • 475. TNK Therapeutics
  • 476. Tongji University School of Medicine
  • 477. Touchstone Innovations
  • 478. TRACT Therapeutics
  • 479. TrakCel
  • 480. Transgene
  • 481. Transposagen Biopharmaceuticals
  • 482. Triumvira Immunologics
  • 483. T. Rowe Price Associates
  • 484. TVAX Biomedical
  • 485. TVM Capital
  • 486. Two Blades Foundation
  • 487. Txcell
  • 488. UNC Lineberger Comprehensive Cancer Center
  • 489. Union Stem Cell & Gene Engineering
  • 490. Universal Cells
  • 491. University College London
  • 492. University Health Network, Toronto
  • 493. University of Birmingham
  • 494. University of British Columbia
  • 495. University of California
  • 496. University of Florida
  • 497. University of Lausanne
  • 498. University Medical Center Utrecht
  • 499. University of Milano-Bicocca
  • 500. University of Minnesota
  • 501. University of Pennsylvania
  • 502. University of Sydney
  • 503. University of Texas
  • 504. University of Zurich
  • 505. Uppsala University
  • 506. Unum Therapeutics
  • 507. Utrecht Holdings
  • 508. Vaccinogen
  • 509. Valeant Pharmaceuticals
  • 510. Vecura
  • 511. Venrock
  • 512. Versant Ventures
  • 513. Vertex Pharmaceuticals
  • 514. VGXI
  • 515. Vical
  • 516. Viking Global Investors
  • 517. ViroMed
  • 518. Vitruvian Networks
  • 519. Vor Biopharma
  • 520. Washington University
  • 521. Weill Cornell Medical College
  • 522. Wellcome Trust
  • 523. Wellington Capital Management
  • 524. WindMIL Therapeutics
  • 525. Woodford Investment Management
  • 526. Wuhan Union Hospital
  • 527. Wuhan Sian Medical Technology
  • 528. WuXi AppTec
  • 529. X-Body
  • 530. Xinqiao Hospital of Chongqing
  • 531. Xijing Hospital
  • 532. Xuzhou Medical University
  • 533. Yale University
  • 534. Zelluna Immunotherapy
  • 535. Zhejiang Huahai Pharmaceutical
  • 536. Zhejiang University
  • 537. Zhujiang Hospital
  • 538. ZIOPHARM Oncology
Back to Top